ABVC Biopharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ABVC Nasdaq 8731 https://abvcpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ABVC Biopharma Inc

ABVC BioPharma Provides Vitargus® Update on Phase II Site Initiation Visit Conducted at Srinagarind Hospital in Thailand - Mar 20th, 2023 11:00 am
ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare - Mar 14th, 2023 11:00 am
ABVC BioPharma Provides 2023 Pipeline Update - Feb 28th, 2023 1:30 pm
ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials - Feb 23rd, 2023 9:16 pm
ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus® - Feb 21st, 2023 1:30 pm
ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference - Jan 19th, 2023 1:30 pm
ABVC: Several Potential Paths to Achieving Near-Term Milestones - Jan 18th, 2023 1:25 pm
FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer - Jan 5th, 2023 1:30 pm
ABVC: Key Medical Venues Participating in Clinical Studies - Dec 20th, 2022 4:05 pm
ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval - Nov 17th, 2022 1:30 pm
ABVC BioPharma Third Quarter 2022 Earnings: Beats Expectations - Nov 17th, 2022 10:16 am
ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results - Nov 14th, 2022 11:20 pm
ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD) - Nov 7th, 2022 1:30 pm
Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma’s Medication for Treating Depression in Cancer Patients - Nov 2nd, 2022 12:30 pm
ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia - Oct 5th, 2022 12:30 pm
ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval - Sep 23rd, 2022 12:30 pm
ABVC: Moving Lead Assets Forward and Expanding Development Pipeline - Sep 16th, 2022 1:36 pm
ABVC Biopharma Announces Letter to Shareholders - Sep 13th, 2022 12:30 pm
ABVC BioPharma Selects Additional Vitargus® Phase II Study Site - Sep 9th, 2022 12:30 pm
ABVC Provides Oncology Pipeline Updates - Aug 22nd, 2022 12:30 pm